全文获取类型
收费全文 | 36196篇 |
免费 | 5497篇 |
国内免费 | 858篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 390篇 |
妇产科学 | 328篇 |
基础医学 | 3841篇 |
口腔科学 | 43篇 |
临床医学 | 3206篇 |
内科学 | 1033篇 |
皮肤病学 | 178篇 |
神经病学 | 80篇 |
特种医学 | 1675篇 |
外国民族医学 | 74篇 |
外科学 | 4844篇 |
综合类 | 4884篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 1538篇 |
眼科学 | 57篇 |
药学 | 2025篇 |
31篇 | |
中国医学 | 676篇 |
肿瘤学 | 17578篇 |
出版年
2024年 | 88篇 |
2023年 | 575篇 |
2022年 | 914篇 |
2021年 | 1964篇 |
2020年 | 1831篇 |
2019年 | 1576篇 |
2018年 | 1505篇 |
2017年 | 1552篇 |
2016年 | 1676篇 |
2015年 | 2007篇 |
2014年 | 2494篇 |
2013年 | 2659篇 |
2012年 | 2067篇 |
2011年 | 2203篇 |
2010年 | 1661篇 |
2009年 | 1579篇 |
2008年 | 1602篇 |
2007年 | 1714篇 |
2006年 | 1733篇 |
2005年 | 1562篇 |
2004年 | 1289篇 |
2003年 | 1247篇 |
2002年 | 1032篇 |
2001年 | 910篇 |
2000年 | 729篇 |
1999年 | 633篇 |
1998年 | 506篇 |
1997年 | 487篇 |
1996年 | 401篇 |
1995年 | 335篇 |
1994年 | 250篇 |
1993年 | 228篇 |
1992年 | 190篇 |
1991年 | 183篇 |
1990年 | 130篇 |
1989年 | 117篇 |
1988年 | 115篇 |
1987年 | 102篇 |
1986年 | 102篇 |
1985年 | 122篇 |
1984年 | 94篇 |
1983年 | 60篇 |
1982年 | 81篇 |
1981年 | 83篇 |
1980年 | 42篇 |
1979年 | 40篇 |
1978年 | 30篇 |
1977年 | 20篇 |
1976年 | 18篇 |
1975年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
47例原发性乳腺癌多药耐药MDR1基因表达及其临床意义 总被引:3,自引:0,他引:3
[目的]探讨原发性乳腺癌多药耐药MDR1基因的表达及其临床意义.[方法]采用荧光定量RT-PCR法检测47例乳腺癌组织及15例正常对照(包括5例乳腺纤维腺瘤、10例癌旁组织)MDR1基因的表达.[结果]乳腺癌MDR1基因表达阳性率为46.8%,与病人年龄、肿瘤大小、淋巴结转移与否、ER、PR状况、绝经与否无关.对照组中无MDR1基因表达.[结论]乳腺癌MDR1基因的表达可作为乳腺癌化疗耐药的评价指标,能否作为判断预后的独立指标尚需进一步研究. 相似文献
72.
对218例女性乳癌术后进行了十年以上的随访观察。随访率为95.87%。术后总的十年生存率为54.87%。Ⅰ期为85.71%,Ⅱ期为53.09%。Ⅲ期为30.76%。阐明了术后疗效与妊娠哺乳,肿瘤部位,肿瘤大小,临床期别,淋巴结转移情况及病理类型有明显关系。讨论了手术方式对术后的影响,提示扩大根治术对Ⅰ、Ⅱ期乳癌并无明显优越性。 相似文献
73.
目的:分析T1期(肿瘤直径<2cm)原发性乳腺癌女性患者绝经前后在肿瘤大小、病理分类、淋巴结转移率和数目。方法:常规病理检验以及应用免疫组化、HE法分别测定绝经前乳腺癌患者和绝经后乳腺癌患者者的ER、PR。结果:两组患者在肿瘤大小上无明显差异,但绝经前乳腺癌患者浸润导管癌的百分比为 84. 7%,绝经后乳腺癌患者的浸润导管癌百分比为 62. 2%,经χ2 检验,P<0. 01。两组淋巴结转移率分别为 39. 3%和 25. 5%,经χ2 检验,P<0. 01。两组ER和PR阳性伴淋巴结转移的比例经χ2 检验,P<0. 05。结论:绝经前乳腺癌患者和绝经后乳腺癌患者在病理分类、淋巴结转移率及数目、ER、PR阳性伴淋巴结转移上有显著性差异。对于T1原发性乳腺癌患者不论有无淋巴结转移,均应行癌肿切除伴Ⅰ、Ⅱ级淋巴结清扫。 相似文献
74.
75.
Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world. Despite many undeniable therapeutic successes obtained, breast cancer still remains, however, a major health issue. In the last few years, thanks to aromatase inhibitors, the hormone therapy for oestrogen-dependent breast cancer has evolved in terms of efficacy and tolerability; at the same time, it has enabled us to better define the role of oestrogens in the etiopathogenesis of this tumour. Weight increase and obesity have been identified as the most important risk and prognostic factors for breast cancer in postmenopausal women. Several hypotheses have been proposed to explain the association of obesity with postmenopausal breast cancer. A more recent hypothesis suggests that adipocytes and their autocrine (paracrine and endocrine actions) are at the centre of such an etiopathogenetic mechanism. A better understanding of the main mechanisms that link together menopause, body-weight increase and hormone-dependent breast cancer is paramount to enable the identification of key molecules involved in the development of breast carcinoma and suggest new therapeutic options. The present review will discuss important findings on the therapeutic aspects of adipose tissue and adipokines as a target for treatment of hormone-dependent breast cancer. 相似文献
76.
Objective: To study the diagnostic value of T2^*-weighted first-pass perfusion imaging in breast tumors. Methods: We analyzed the magnetic resonance imaging (MRI) information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^*-weighted first-pass perfusion imaging. The curve's maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results: Malignant breast lesions showed higher maximal signal intensity drop rate (44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001) than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions (23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05). Conclusion: The T2^*-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis. 相似文献
77.
原位杂交法检测BP1基因在乳腺癌组织中表达 总被引:3,自引:0,他引:3
目的探讨BP1同源盒基因在乳腺癌中的表达及其与临床病理指标的关系。方法收集165例乳腺癌临床和病理资料,采用原位杂交法检测BP1的表达,同时用二步法进行ER、p53、PCNA、bcl2、cerbB2免疫组化染色。结果BP1基因表达率为67.88%,免疫组化:ER70.30%、p5349.09%、PCNA74.55%、bcl253.33%、cerbB275.52%。BP1与bcl2具有相关性(P<0.01),且均与ER相关(P<0.05),与p53呈负相关(P<0.05)。BP1与PCNA、cerbB2、患者年龄、组织学类型、淋巴结转移等无相关性。结论BP1可能通过某种非依赖p53基因调控机制,与bcl2、ER协同抑制肿瘤细胞的凋亡而参与乳腺癌的发生。 相似文献
78.
J.P. Brouillet B. Hanslick T. Maudelonde M.T. Pivat J. Grenier F. Blanc H. Rochefort 《Clinical biochemistry》1991,24(6):491-496
Using a sandwich enzyme-linked immunoassay, plasma total cathepsin D concentration was assayed in 40 breast cancer patients and 84 patients with various liver diseases and compared to that of 52 normal subjects. There were no significant variations found in breast cancer patients related to tumor size, node invasiveness or metastases. In normal women, cathepsin D levels were slightly but not significantly increased in the luteal phase and in pregnancy. By contrast, plasma cathepsin D concentration was significantly increased in 70-75% of patients with liver disease (cirrhosis, hepatocarcinoma, hepatitis), but not in those with liver steatosis. Cathepsin D was independent of most of the plasma hepatic function tests and was correlated with alpha-fetoprotein in cirrhosis and with alpha-fucosidase in primary hepatocellular carcinoma. We conclude that plasma cathepsin D is not a useful marker in breast cancer. However, since the cellular level of this protease is associated with risk of metastasis in breast cancer, clinical follow-up will be required to test whether high cathepsin D plasma concentration has any prognostic value in liver cirrhosis and primary hepatocarcinoma. 相似文献
79.
Yanli Song Dong Wang 《中国肿瘤临床(英文版)》2007,4(2):142-144
OBJECTIVE To investigate the effect of neoadjuvant chemotherapy in treatment of Stage Ⅱ breast cancer.
METHODS The data from 113 patients with breast cancer of the same pathologic type in Stage Ⅱ,during the period of 1995 to 2001,were analyzed retrospectively.Among the patients,47 were treated with neoadjuvant chemotherapy,and 66 received no adjuvant therapy before surgery(control group).After the patients of the neoadjuvant chemotherapy group had received 2 courses of chemotherapy with the CMF regimen,the surgical procedure was conducted.
RESULTS Complete remission(CR)was attained in 9 of the 47 cases receiving neoadjuvant chemotherapy and partial remission(PR)was reached for 22 cases.The rate of breast-conserving surgery was enhanced from 22.73%to 46.81%(P〈0.05)in the neoadjuvant treatment group.
There was no difference in the 5-year overall survival(OS)and disease-free survival(DFS)rate between the two groups(P〉0.05),but the 5-year OS and DFS of the cases with clinical tumor remission was higher compared to the control group(P〈0.05).
CONCLUSION Neoadjuvant chemotherapy can enhance the rate of breast conservation for Stage Ⅱ breast cancer and may improve the prognosis of the cases with clinical remission. 相似文献
80.
目的:探讨靶重建放大扫描技术对肺孤立性结节病变的诊断价值。方法:对63例患者先行常规CT平扫,选定结节处为兴趣区,行薄层靶重建放大扫描,层厚、层距为2mm,FOV为160。结果:42例恶性病变中有37例表现为深分叶,占88.1%;21例良性病变中有15例表现为浅分叶,占71.4%。恶性结节中15例内部出现条状低密度支气管征;7例出现血管集中征;8例出现空泡征;病变内部出现液化坏死13例,其中恶性病变ll例。22例出现钙化,包括12例良性病变和10例恶性病变。2例错构瘤内均见小面积脂肪性低密度影。结论:靶重建放大扫描比普通CT扫描可提供更多的信息,对良恶性病变的鉴别诊断有一定价值。恶性病变大多数为深分叶,良性病变大多数为浅分叶或无分叶。 相似文献